At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CFO’ operating in the Biopharma space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
C. Evan Ballantyne
Chief Financial Officer of OncXerna Therapeutics
C. Evan Ballantyne is the chief financial officer of [Agenus](https://www.crunchbase.com/organization/agenus), a biotechnology company that develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. Previously, he worked as the CEO of Synthetic Biologics. Ballantyne served as the CFO and executive vice president of Trovis Pharmaceuticals from 2006, before which he was the CFO of Knowledge Impact, ZymeQuest, Clinical Data, Velico Medical, Avalon Pharmaceuticals, and AcNielsen Corporation. Ballantyne holds a bachelor’s degree in political sciences and American history from the University of Western Ontario and a post-graduate degree in business administration from the University of Windsor.
Follow C. Evan Ballantyne:
About OncXerna Therapeutics: OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
Richard Vellacott
Chief Financial Officer of Horizon Discovery
Richard has over 15 years’ experience as a chartered accountant, working with life science companies from start-ups to global pharmaceuticals. He also has a first class degree in biological sciences from Durham University. Past roles include Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of a NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Beyond his corporate responsibilities, Richard has advised the EC on funding for life science companies and presented at investor conferences and technical seminars on financial issues facing the life science industry.
Follow Richard Vellacott:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Howard Liang
President and CFO of Tessera Therapeutics
Follow Howard Liang:
About Tessera Therapeutics: Tessera Therapeutics is an early-stage life sciences company.
Manmeet S. Soni
Chief Financial Officer of Reata Pharmaceuticals
CFO/EVP at Reata Pharmaceuticals.
Follow Manmeet S. Soni:
About Reata Pharmaceuticals, Reata Pharmaceuticals: Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Eric Shaff
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Ted Myles
Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Ted Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Ted Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Ted Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Ted Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers. He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Ted Myles became a CPA in 1996.
Follow Ted Myles:
About AMAG Pharmaceuticals: AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of therapeutic.
Ola Soderquist
CFO/Controller & Co-founder of Oxygen Therapy
Follow Ola Soderquist:
About Oxygen Therapy: Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.